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Background/aim: The TReasure registry, created in 2017, is an observational multicenter cohort that includes inflammatory arthritis 
patients. This article reviews the methodology and objectives of the TReasure registry established to collect data from rheumatoid 
arthritis (RA) and spondyloarthritis (SpA) patients.
Methodology: Fifteen rheumatology centers in Turkey will contribute data to the TReasure database. The actual proprietor of the 
database is the Hacettepe Rheumatology Association (HRD) and Hacettepe Financial Enterprises. Pharmaceutical companies that 
operate in Turkey (in alphabetical or er), Abbvie, Amgen, BMS, Celltrion Healthcare, Novartis, Pfizer, Roche, and UCB, support the 
TReasure registry. TReasure is a web-based database to which users connect through a URL (https://www.trials-network.org/treasure) 
with their unique identifier and passwords provided for data entry and access. TReasure records demographic and clinical features, 
comorbidities, radiology and laboratory results, measures of disease activity, and treatment data.
Discussion: TReasure will provide us with various types of data, such as a cross-sectional view of the current nationwide status of the 
patients currently receiving these treatments, and retrospective data as much as allowed by the participating centers’ records. Finally, a 
high-quality prospective dataset will be built over the ensuing years from patients with a new diagnosis of RA or SpA. 
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1. Introduction 
Registry of clinical, laboratory, and treatment features of 
chronic diseases is a significant achievement of modern 
medicine gained through informatics. Inflammatory 
arthritis is one example of such chronic diseases. 
Information concerning the broad nature and progress 
of arthritis can be collected thanks to regular registry and 
follow-ups. Monitoring patients at regular intervals and 
systematic, structured, long-term observations contribute 
to improvement in patient care and achieving a high-level 
standard. Observing patients’ and clinicians’ treatment 
choices, effects of treatment, and, more to the point, 
possible harms may help alert the patients and clinicians 
at early stages. Registries in rheumatology started around 
the early 2000s. These registries were established in single 
centers or assumed international multicenter structures. 
Registries for inflammatory arthritis were established in 
England, France, Germany, Sweden, Denmark, Italy, the 
United States, and South America (1–8). By this means, 
as an outstanding example, we understood that proper 
implementation of latent tuberculosis treatment decreases 
the risk of tuberculosis reactivation (9).  
The Hacettepe University Biologics Registry (HUR-
BIO) has recorded patients on biologic disease-modifying 
antirheumatic drug (bDMARD) treatments as a single 
center since 2005 (10). As of March 2017, approximately 
2200 spondyloarthritis (SpA) and 1400 rheumatoid 
arthritis (RA) patients on bDMARD treatments were 
registered in the HUR-BIO registry. Since single-center 
registries record their entries in a uniform manner, there 
is not a problem of missing data. On the other hand, there 
are some disadvantages, such as not being widespread 
throughout the country and not being able to monitor 
externally. For this reason, starting from March 2017, to 
embrace other rheumatology centers, the widening of the 
HUR-BIO database has been mapped out. This article 
reviews the methodology and objectives of the TReasure 
registry established to collect data from RA and SpA 
patients.
2. Methodology
2.1. Administrative, financial, and ethical matters
Fifteen rheumatology centers in Turkey will contribute 
data to the TReasure database. The actual proprietor 
of the database is the Hacettepe Rheumatology 
Association (HRD) and Hacettepe Financial Enterprises. 
Pharmaceutical companies that operate in Turkey (in 
alphabetical order), Abbvie, BMS, Celltrion Healthcare, 
Pfizer, Roche, and UCB, support the TReasure registry. 
TReasure is a web-based database to which users connect 
through a URL (https://www.trials-network.org/treasure) 
with their unique identifier and passwords provided for 
data entry and access. Each center can access previously 
contributed data from the patients under their follow-up. 
The coordinating center can monitor the entirety of the data 
from all centers. Omega Research Organization Training 
and Counseling Ltd. handles all required correspondence 
with ethics committees and external monitoring. Local 
ethics committee approval for the TReasure database was 
obtained in May 2017 from Hacettepe University (KA-
17/058) and in October 2017 from the Ministry of Health 
of Turkey (93189304-14.03.01)
2.2. Features of the database 
2.2.1. General features of TReasure
TReasure is intended as a prospective observational cohort 
with two major subcohorts for RA and SpA. Demographic 
information, birthdate, sex, contact information, 
educational status, and social security information are 
recorded for all RA and SpA patients deemed eligible.
2.2.2. Eligibility criteria for TReasure
At the time of manuscript preparation, TReasure started 
recording RA and SpA patients. Currently the database 
records prevalent patients on conventional synthetic 
DMARD (csDMARD), bDMARD, and targeted synthetic 
DMARD (tsDMARD) treatments. After the study kick-
off we plan to record all patients starting tsDMARD or 
bDMARD treatments. We also plan to record patients 
that are prevalent users of tsDMARDs and bDMARDs 
attending outpatient clinic visits. For every 10 patients using 
a tsDMARD or bDMARD, 3 patients using csDMARDs 
will be registered in the system. Written informed consent 
will be obtained from all participants before cohort entry. 
2.2.3. Diagnosis
Two sets of classification criteria will be applied for 
RA diagnosis. These are the 1987 American Colleague 
of Rheumatology (ACR) criteria (11] and the 2010 
European League Against Rheumatology (EULAR)/ACR 
classification criteria (12). Otherwise the clinical diagnosis 
of the rheumatologist will also be accepted. With respect to 
SpA diagnoses, patients fulfilling the modified New York 
criteria are eligible (13); for axial SpA, the 2009 EULAR 
axial SpA classification criteria (14) as well as the peripheral 
SpA classification criteria (15) are eligible. Classification 
criteria for psoriatic arthritis (CASPAR) criteria will be 
utilized to validate psoriatic arthritis (PsA) diagnoses 
(16). For patients with enteropathic arthritis, evidence for 
a diagnosis of Crohn’s disease or ulcerative colitis will be 
sought in addition to peripheral joint involvement or axial 
involvement.
2.2.4. Comorbidities
TReasure records a prespecified set of comorbid diseases for 
both RA and SpA patients. Namely, these are hypertension 
(date of diagnosis, current drugs), diabetes mellitus (date 
of diagnosis, current drugs, current status of microvascular 
complications), osteoporosis (results of bone densitometry 
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and osteoporosis drugs), dyslipidemia (date of diagnosis, 
lipid-lowering medications, lipid profile), kidney disease 
(creatinine and estimated glomerular filtration rate (GFR)), 
chronic pulmonary disease (COPD and asthma), thyroid 
diseases, cardiovascular disease (myocardial infarction, 
congestive heart failure, valvular disease, diagnoses, and 
treatments), presence of thromboembolic disease and 
sites of involvement, peptic ulceration and gastrointestinal 
bleeding, chronic liver disease, type and date of cancer, 
presence of amyloidosis, neurologic conditions (dementia, 
cerebrovascular accident), presence of acquired immune 
deficiency syndrome (AIDS), and previous surgery. 
A baseline Charlson Comorbidity Index score will be 
calculated for each patient and updated longitudinally as 
additional comorbidity occurs (17).
2.2.5. Rheumatoid arthritis extraarticular involvement
TReasure records prevalent and new extraarticular 
involvement in patients with RA. For interstitial lung 
disease, date of onset and diagnosis, physical examination 
findings, score of labored breathing (Borg scale), 
spirometry results, and findings from chest radiography 
and computed tomography imaging are recorded (18). 
Other extraarticular findings that will specifically 
be sought include skin ulceration and subcutaneous 
nodules, neurologic deficits (entrapment neuropathy, 
atlantoaxial involvement, peripheral nervous system 
involvement, central nervous system involvement), Felty’s 
syndrome, scleritis, Sjögren’s syndrome, and hematologic 
abnormalities.
2.2.6. Spondyloarthritis examination and extraarticular 
involvement
TReasure records the presence of inflammatory back 
pain (as per Calin, ASAS, and Berlin criteria) (19–21), 
enthesitis (as specified in the Leeds Enthesis Index (LEI)) 
(22), peripheral arthritis, and dactylitis. In addition, 
extraarticular involvement such as uveitis (date of 
first attack, number of attacks, presence of permanent 
damage, site and extent of involvement), inflammatory 
bowel disease (Crohn’s disease, ulcerative colitis, and 
indeterminate colitis), psoriasis (affected skin area, nail 
involvement), and presence of familial Mediterranean 
fever (FMF) (clinical symptoms, response to colchicine 
treatment, MEFV mutation) are also recorded. Family 
history of SpA, psoriasis, and FMF will also be included. 
2.2.7. Radiology and laboratory results
TReasure records the presence of erosions in hand and feet 
radiographs. Participating centers also perform and record 
the results of an ultrasound scan of the wrist and the 2nd 
metacarpophalangeal and 5th metacarpophalangeal joints 
for patients who are to initiate bDMARD or tsDMARD 
treatments. Highest values of RF and anticyclic citrullinated 
peptide (anti-CCP) values from first diagnosis up until 
registration are recorded. 
Centers record the degree of sacroiliitis in pelvic 
X-ray, presence of syndesmophytes in the spinal column, 
reduction in hip joint space (none, mild, medium, severe, 
in need of prosthesis), findings from sacroiliac MRI scans 
(active and chronic changes indicating sacroiliitis), and 
results of human leucocyte antigen (HLA)-B27 tests for 
patients with AS.
2.2.8. Measures of disease activity
A battery of RA core domain items are recorded in TReasure 
in order to longitudinally follow disease activity. Namely, 
these are tender and swollen joint counts in 66 and 68 
joints respectively, the Health Assessment Questionnaire 
Disability Index (HAQ-DI) (23), patient global assessment 
of overall disease activity-visual analog scale (VAS) (0–100 
mm), pain-VAS (0–100 mm), physician global assessment 
of overall disease activity-VAS (0–100 mm), fatigue-VAS 
(0–100 mm), and morning stiffness (duration in minutes 
and severity). Acute phase response markers, erythrocyte 
sedimentation rate (ESR) (mm/h), and C-reactive protein 
(CRP) (mg/dL) are also recorded. Using these core domain 
items, the following composite disease activity measures 
are calculated: Disease Activity Score (DAS)-28-ESR and/
or DAS-28-CRP (24), Simplified Disease Activity Index 
(SDAI), and Clinical Disease Activity Index (CDAI) (25).
The battery is different for patients with SpA. It 
includes back pain-VAS (0–100 mm), peripheral pain/
swollen joint-VAS (0–100 mm), count of fingers with 
dactylitis, morning stiffness (duration in minutes and 
severity), overall pain-VAS (0–100 mm), physician 
global assessment -VAS (0–100 mm), patient global 
assessment VAS (0–100 mm), fatigue-VAS (0–100 mm), 
and swollen and tender joint counts as in RA. Acute phase 
reactants, ESR (mm/h), and CRP (mg/dL) are recorded. 
Featured composite outcome/activity indices are the Bath 
Ankylosing Spondylitis Activity Index (BASDAI) (26), 
Bath Ankylosing Spondylitis Functional Index (BASFI) 
(27), HAQ-DI (25), ASAS disease activity scale as ASDAS-
ESR (28) and ASDAS-CRP (28), EQ-5D (29), LEI (22), 
and ASAS life quality index (30). For PsA patients an 
additional small battery consisting of PsAID-12 (31) and 
PSI (32) is assessed.
2.2.9. Treatment data
TReasure utilizes a similar data entry procedure for all 
treatments in RA and SpA. All csDMARDs have a dose, 
route of administration, start and end dates, and reason 
for cessation if treatment is stopped. For nonsteroid 
antiinflammatory drugs (NSAIDs), the compound, daily 
average dose, and weekly frequency of use are noted. 
Dosage and duration of glucocorticoids are also recorded. 
Among bDMARDs, all products licensed in Turkey, 
namely abatacept, adalimumab, anakinra, canakinumab, 
certolizumab, etanercept, golimumab, infliximab, 
rituximab, secukinumab, tocilizumab, and ustekinumab, 
859
KALYONCU et al. / Turk J Med Sci
are noted. Currently the only licensed tsDMARD in 
Turkey is tofacitinib.
2.2.10. Visit data
As per the social security reimbursement regulations for 
bDMARDs or tsDMARDs in Turkey, patients receiving 
any of these medications must be examined/evaluated 
by their providers every 3 months and new treatment 
prescribed if need be. For this reason, our prospect is to 
record patients’ visits every 3 months. However, since the 
database reflects real life, data will be entered as encounters 
occur. Each visit record will include the currently received 
csDMARD, tsDMARD, and bDMARD so that treatment 
switches, cessations, and initiations can be easily tracked 
with good temporal resolution.
In the event that the attending clinician decides to stop 
bDMARD or tsDMARD treatment, the reason for treatment 
cessation will be recorded. These reasons are categorized 
as inefficiency, decision to conceive, physician’s request, 
adverse events, and others. In the case of inefficiency, data 
about the type of inefficiency, primary or secondary, will be 
recorded. Adverse events are categorized as injection site 
reactions, infusion reactions, infections (life-threatening, 
requiring hospitalization, requiring parenteral treatment 
with antibiotic/antiviral/antifungal drugs, or prolonging 
hospital admission), psoriasis, systemic lupus or lupus-
like events, uveitis, reactivation tuberculosis, neurologic 
events, cancer, abnormal liver function tests, leukopenia, 
thrombocytopenia, anemia, gastrointestinal adverse 
events, and others. 
2.3. Studies in progress 
At the time of manuscript preparation, 24 observational 
study proposals were submitted to the TReasure 
administration; 21 of these were from the collaborating 
centers and three were from the pharmaceutical industry. 
A descriptive account of demographic and clinical 
information of patients receiving csDMARD, tsDMARD, 
and bDMARD treatments is currently underway. This 
exercise, in addition to describing the overall TReasure 
cohort, will also include the current disease activity status 
with each drug/combination, drug survival, and differences 
in baseline characteristics of individuals receiving various 
treatments.
One major topic of studies in progress is the association 
between patient characteristics and treatment response. 
Two such studies will explore separately for RA and SpA 
the response to various treatments by comorbidity load 
as defined by the items of Charlson Comorbidity Index. 
A number of studies will explore extraarticular RA cases 
such as interstitial lung disease (ILD), clinical features, 
and influence on treatment selection, as well as the 
relation between various treatments and ILD progression/
prognosis, and secondary Sjögren’s syndrome and its 
relationship with RA clinical course and treatment response. 
csDMARD prescription for axial spondyloarthritis is not 
uncommon in Turkey. Extrapolating from studies on RA, 
one of the collaborating groups aims to study the effect of 
csDMARD use on bDMARD efficacy and drug survival 
in SpA patients. Another participating center launched 
a descriptive study of enteropathic arthritis patients and 
their response to new-generation treatments, a topic at 
large unexplored in large-scale studies.
Another major topic is the treatment of inflammatory 
arthritis subpopulations. One such study will describe the 
SpA subpopulation with uveitis and explore the risk factors 
and course. Another study will compare and contrast RA 
and SpA patients with diabetes in order to understand 
whether and how the clinical course and treatment 
response in this subpopulation is altered. Although RA is a 
disease of the middle aged, late-onset disease has a distinct 
clinical course. One study will explore the characteristics 
and treatment response in geriatric patients, including 
both late-onset RA and early-onset patients in the geriatric 
age category.
Harms is also a major topic of study proposals 
submitted to the TReasure administration. A number of 
studies will explore severe infections, tuberculosis, risk of 
thromboembolic complications, the risk of and measures 
for protection against viral hepatitis reactivation, and 
demyelinating disorders after treatment with tsDMARDs 
and bDMARDs. One study will explore the risk of 
paradoxical treatment responses with bDMARDs 
such as granulomatous inflammation or psoriasis-like 
skin changes. Finally, a descriptive study will focus on 
treatment selection and response in SpA patients with a 
recent history of cancer.
3. Discussion
The TReasure registry, created in 2017, is an observational 
cohort that includes inflammatory arthritis patients 
using csDMARD, bDMARD, and tsDMARD treatments. 
It involves 15 centers that see patients on a regular 
basis in Turkey and currently about 5000 patients are 
receiving bDMARD and tsDMARD treatments in these 
centers regularly. The registry includes patients receiving 
csDMARDs as well as patients receiving bDMARD 
or tsDMARD treatments. All patients receiving any 
bDMARD or tsDMARD treatment enter the registry. 
TReasure will provide us with various types of data. First, 
patients with prevalent bDMARD or tsDMARD treatment 
newly registered by the participating centers can be 
expected to provide a cross-sectional view of the current 
nationwide status of the patients currently receiving these 
treatments. For instance, the clinical features of patients 
who have uveitis and risk factors that might be related 
to it can be obtained cross-sectionally. Secondly, these 
prevalent patients will also provide retrospective data as 
much as allowed by the participating centers’ records. 
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Finally, as patients with a new diagnosis of RA or SpA 
initiating csDMARD treatment and patients with new 
bDMARD or tsDMARD treatment enter the TReasure 
database, a high-quality prospective dataset will be built 
over the ensuing years. Using these prospective data, for 
example, we will have an opportunity to describe varying 
treatment responses with different treatment modalities 
in geriatric patients or understand the risks of severe 
infections, cancers, or neurologic complications of new 
treatment modalities over the long term. Another prospect 
is to take advantage of the single-payer healthcare system 
in Turkey by linking the TReasure database data with 
social security billing information and population records 
in order to study long-term hard outcomes such as joint 
surgery, cardiovascular events, and overall mortality. 
Such linkages could provide invaluable information with 
very good accuracy, much less effort, and more efficiency 
as compared to a prospective database built for such 
purposes. Finally, a well-structured prospective database 
could be a very useful resource to find and recruit patients 
for randomized controlled trials for new treatments or 
even perform opportunistic trials to test new treatment 
strategies. We intend to share our observations in national 
and international periodicals and conferences.
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